TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03781596

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone
Description: Participants in the experimental and placebo arms will be given swallowed fluticasone for an 8 week course. Doses determined by age and weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: The participants in the experimental arm will be given oral omprazole capsules for an 8 week period (along with the swallowed fluticasone). Doses determined by age and weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The participants in the placebo arm will be given placebo capsules for an 8 week period (along with the swallowed fluticasone). Number of pills determined by age and weight (to match omeprazole dosing).
Study: NCT03882450

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible fiberoptic laryngoscopy
Description: Flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if the participant is not intubated and is stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal ultrasonography
Description: Laryngeal ultrasonography will be performed using a portable ultrasound system while the participants are awake.
Study: NCT03185052

Intervention type: OTHER
Group type: OTHER
Intervention: Manual puncture point compression
Description: Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
Study: NCT02019459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard nicotine content cigarettes
Study: NCT02757469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone and ethinyl estradiol combination (Yasmin)
Description: Female oral combined contraceptive containing 30 mcg (0.030 mg) Ethinyl Estradiol and 3 mg drospirenone (Androstenes)
Study: NCT03449771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-administered questionnaire
Description: The newsletter and a self-questionnaire will be systematically given in the waiting room to any PrEP consultant to evaluate the consumption of psychoactive substances (ASSIST questionnaire) and to identify anxio-depressive disorders (HAD questionnaire - Hospital Anxiety and Depression). scale).
Study: NCT01333605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGEV
Description: Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles.
Study: NCT00679770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690, 2.5%
Description: Once daily application for 90 days and 3 x weekly for 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690, 5%
Description: Once daily application for 90 days and 3 x weekly for 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690, 7.5%
Description: Once daily application for 90 days and 3 x weekly for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Once daily application for 90 days and 3x weekly for 90 days
Study: NCT02681900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation manipulation task
Description: Participants in the self-affirmation condition indicate their most important value, give three examples of why this value is important to them and one example of something they had done to demonstrate its importance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control task
Description: People in the control condition indicate their least important value, three examples of why that value could be important to someone else, and describe something that person could do to show its importance.
Study: NCT01715194

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine intervention
Description: Patients undergoing telemedicine intervention
Study: NCT02463994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: Patients will receive 1,200 mg I.V. Q 3 weeks of MPDL3280A until progression.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Description: Hypofractionated Image-Guided Radiotherapy (HIGRT)
Study: NCT01550029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling/Managing Mood
Description: A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting.
Study: NCT03888781

Intervention type: DEVICE
Intervention: Echocardiography
Description: An echocardiogram (also called an echo) is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of your heart. These echoes are turned into moving pictures of your heart that can be seen on a video screen.

Intervention type: DEVICE
Intervention: Echocardiography
Description: An echocardiogram (also called an echo) is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of your heart. These echoes are turned into moving pictures of your heart that can be seen on a video screen.
Study: NCT00746876

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unipolar hip hemiarthroplasty
Description: Unipolar hip hemiarthroplasty for the treatment of femoral neck fractures

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar hip hemiarthroplasty
Description: Bipolar hip hemiarthroplasty for the treatment of femoral neck fractures
Study: NCT02292173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Dose Escalation:~Level 1: 1 mg daily. Level 2: 1.5 mg daily. Level 3: 1.5 mg daily. Level 4: 2 mg daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Dose Escalation:~Level 1: 200 mg twice daily. Level 2: 200 mg twice daily. Level 3: 400 mg twice daily. Level 4: 400 mg twice daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)
Study: NCT04448652

Intervention type: DRUG
Intervention: NSAID
Description: no other intervention than described in the groups.
Study: NCT03840369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation to Right Dorsolateral Prefrontal Cortex
Description: Transcranial magnetic stimulation (TMS) works by delivering a magnetic pulse to a focal brain region. TMS has a high degree of safety and has been studied as an intervention for many mental health and neurological conditions. Repetitive TMS (rTMS) delivers pulses at a set time interval in order to modulate neural activity in that region.
Study: NCT01687751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~* The study drug will be started at a rate of 1.0 mL/hr.~* The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate \< 40) or hypotension (systolic blood pressure \< 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse
Study: NCT03840369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: The sham TMS coil will make a similar sound to the real rTMS coil, but will not deliver a magnetic pulse. This is a no-treatment device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: The sham TMS coil will make a similar sound to the real rTMS coil, but will not deliver a magnetic pulse. This is a no-treatment device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation to Right Dorsomedial Prefrontal Cortex
Description: Transcranial magnetic stimulation (TMS) works by delivering a magnetic pulse to a focal brain region. TMS has a high degree of safety and has been studied as an intervention for many mental health and neurological conditions. Repetitive TMS (rTMS) delivers pulses at a set time interval in order to modulate neural activity in that region.
Study: NCT03485365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3858279 IV
Description: GSK3858279 will be available as solution for injection to be administered via IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3858279 IV
Description: GSK3858279 will be available as solution for injection to be administered via IV route.
Study: NCT02453152

Intervention type: OTHER
Intervention: Peak cough flow
Description: Subjects' strongest coughs will be measured.

Intervention type: OTHER
Intervention: Pediatric Evaluation of Disability Inventory
Description: Assesses the functional capabilities of children with disabilities.

Intervention type: OTHER
Intervention: PedsQL Multidimensional Fatigue Scale
Description: Assesses general fatigue, sleep/rest fatigue, and cognitive fatigue.

Intervention type: OTHER
Intervention: Review of ventilation requirements
Description: Subjects's use of mechanical ventilation reviewed by the study team.
Study: NCT00854724

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Puerarin, Placebo
Description: 400 mg, three times a day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Puerarin, Placebo
Description: 400 mg, three times a day for 7 days
Study: NCT04897230

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hatha Yoga
Description: The yoga poses were chosen for providing a restorative session based on their purported relationship to restorative effects to best promote cardiac autonomic recovery from mental stress.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Video Watching
Description: The video was about the history of the Earth which encompasses the development of the planet Earth from its formation to the present day.
Study: NCT04491682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Description: At a dosage of 160 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: At a dosage of 10 mg/day
Study: NCT01882556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03839849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: : i-PRF
Description: The description of this intervention has been already given before

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: The description of this intervention has been already given before
Study: NCT02812264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: API App
Description: Mobile application that uses API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-API App
Description: Mobile application that does not use API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fitness tracker
Description: fitness tracker to monitor physical activity and sleep patterns that is connected to transfer data to app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: fitness tracker
Description: fitness tracker to monitor physical activity and sleep patterns that is connected to transfer data to app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: scale
Description: Connected scale that will transfer weight information to app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: scale
Description: Connected scale that will transfer weight information to app
Study: NCT03890926

Intervention type: RADIATION
Intervention: radioactive Iodine-125 seed implantation under the guidance of 3D template
Description: 3D-PNCT assisted with CT-guidance for radioactive Iodine-125 seed brachytherapy is a conventional treatment for patients with local recurrent rectal carcinoma. Retrospective data on the effectiveness and adverse effects of the past radioactive Iodine-125 seed implantation is collected.
Study: NCT04106258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemoporfin PDT
Description: Photodynamic therapy is performed using hemoporfin under general anesthesia. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemoporfin PDT
Description: Photodynamic therapy is performed using hemoporfin under general anesthesia. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
Study: NCT01586598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sensory retraining protocol
Description: 1. within one month after the surgery: facial massage and physical stimulation over lower face and lip, four times (20 minutes each time) a day~2. one to three months after the surgery: brush and physical stimulation over lower face and lip, four times (20 minutes each time) a day~3. three to six months after the surgery: brush, pin and physical stimulation over lower face and lip, four times (20 minutes each time) a day
Study: NCT01379248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manual thrombus aspiration (Export catheter, Medtronic Inc. Minneapolis, Minnesota, USA)
Description: manual thrombus aspiration catheter to be used during percutaneous coronary intervention
Study: NCT04207411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Injection of anesthetics blocks once a week during 4 weeks.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bupivacaine
Description: Injection of anesthetics blocks once a week during 4 weeks.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lidocaine
Description: Injection of anesthetics blocks once a week during 4 weeks.
Study: NCT02706418

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Clinical Massage Therapy
Study: NCT02649959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM-AT
Description: Single unit does powder of active substance (CM-AT) administered 3 times per day
Study: NCT04873141

Intervention type: DRUG
Intervention: Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)
Description: Tocilizumab was given according to weight in patients with cytokinme releasew syndrome (CRS).
Study: NCT01807169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonic polypectomy or endoscopic mucosal resection (EMR).
Description: Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
Study: NCT00343395

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AVANDAMET
Description: 2/500 mg
Study: NCT02171806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03485365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3858279 IV
Description: GSK3858279 will be available as solution for injection to be administered via IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3858279 IV
Description: GSK3858279 will be available as solution for injection to be administered via IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3858279 IV
Description: GSK3858279 will be available as solution for injection to be administered via IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3858279 SC
Description: GSK3858279 will be available as solution for injection to be administered via SC route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3858279 SC
Description: GSK3858279 will be available as solution for injection to be administered via SC route.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching to GSK3858279 (SC or IV)
Description: Placebo will be available as sodium chloride solution to be administered via SC or IV route.
Study: NCT02144402

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: infant formula with DHASCO
Study: NCT03485365

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching to GSK3858279 (SC)
Description: Placebo will be available as sodium chloride solution to be administered via SC route.
Study: NCT02144402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infant formula with DHASCO-B
Study: NCT00331994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus clausii
Description: 3 bacillus clausii vials/day for one month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 3 Metronidazole tablets/day for one week
Study: NCT02318238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6 minutes walking test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 minutes step test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4 meters gait speed
Study: NCT04290975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-shifting of follow-up care for pediatric epilepsy
Description: For the intervention arm, follow-up care of children with epilepsy will be shifted to be performed primarily by Community Health Workers (CHWs) with specialized epilepsy training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care for pediatric epilepsy
Description: For the intervention arm, follow-up care of children with epilepsy will be performed primarily by physicians, with CHWs serving to collect standardized data regarding outcomes
Study: NCT01697475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational text messaging
Description: Motivational text messaging was given for participants in the intervention group - 3 times a day, 3 times a week, for 6 weeks
Study: NCT01687751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~* The study drug will be started at a rate of 1.0 mL/hr.~* The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate \< 40) or hypotension (systolic blood pressure \< 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse
Study: NCT00185445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate (Fludara)
Description: All patients will receive fludarabine phosphate orally for 3 consecutive days per cycle and mitoxantrone on day 1. Each patient will receive up to six treatment cycles. Treatment cycles will be given at 4 weeks intervals.
Study: NCT03910387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given gemcitabine/nab-paclitaxel combination therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given gemcitabine/nab-paclitaxel combination therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given gemcitabine/nab-paclitaxel combination therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Given gemcitabine/nab-paclitaxel combination therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat Ethyl
Description: Given PO
Study: NCT03717025

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SUCTION BLISTER EPIDERMAL GRAFTING
Description: 1. Preferred donor sites for making blister is lateral aspect of upper thigh. The area is shaved and cleansed with surgical spirit.~2. Blister formation is induced by using suction apparatus.~3. Recipient site is surgically prepared by doing dermabrasion.~4. After formation of blisters, each blister is gently cleansed with normal saline and cut all along its border with curved iris scissors parallel to the skin surface. The roof is everted over the thumb with dermal surface facing upwards and then with the help of blunt end of forceps it is placed on the recipient area.~5. The graft is firmly pressed with sterile moist gauze to remove any underneath serous collection.~6. The pressure dressing is done with double layer framycetin tulle, moist gauze and bandage.~7. Donor area is dressed with dry sterile pads.~8. The part is immobilized and Antibiotics and Analgesic are given till dressing are removed (after 5-7 days).
Study: NCT02554201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical pudendal nerve stimulation
Description: Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. Needles of 0.40 Х 100 mm are inserted perpendicularly to the upper points to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The two lower points are about 1 cm bilateral to the tip of the coccyx. Needles of 0.40 Х 100 or 125 mm are inserted obliquely to the lower points towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally needles.
Study: NCT03624335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECC
Description: Early clamping of the umbilical cord
Study: NCT02554201

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal electrical stimulation
Description: A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES